Colossal Biosciences seeks funding at $20-30B valuation for AI-driven de-extinction technology
The AMW Read
A $20-30B valuation for a pre-revenue AI-biology company resets benchmarks for segment 06 (Healthcare/Bio) and meets the hard threshold for cross.§D Capital (valuation >$5B).
Colossal Biosciences seeks funding at $20-30B valuation for AI-driven de-extinction technology
Colossal Biosciences, the Dallas-based startup using genetic engineering and AI to resurrect extinct species such as the dire wolf, is reportedly pursuing new funding at a valuation between $20 billion and $30 billion. The company has not confirmed the terms.
Why it matters: This valuation level — at least 20 times larger than typical biotech AI startups — signals a structural capital-cycle shift in which synthetic biology companies with AI-centered workflows are entering hyperscale territory. Colossal occupies a rare intersection of computational biology, genome engineering, and foundation-model-style data synthesis; the $20-30B figure would place it among the most richly valued private AI-biology companies globally. The raise reflects a broader pattern in which investors treat AI-enabled biological simulation as a frontier infrastructure bet rather than a conventional therapeutics pipeline.
Expert take: The implied valuation is remarkable for a pre-commercial entity, suggesting that backers are pricing the company's proprietary AI models for ancient DNA reconstruction as platform technology. However, no revenue or de-extinction milestone is cited in the report; the raise will test whether the capital market views computational paleogenomics as a repeatable vertical or a one-off moonshot. If Colossal closes at or above $20B, it would reset benchmarks for the AI-biology segment and likely draw new entrants into genome-scale foundation modeling.